Sentigen Holding Corp. Announces Second Quarter Results

Sentigen Holding Corp. (NasdaqSC: SGHL), today reported
results for the quarter and six months ended June 30, 2005.
   On February 22, 2005, we sold the Specialty Media Division of our
wholly-owned subsidiary, Cell & Molecular Technologies, Inc. ("CMT"),
to Chemicon International, Inc., a wholly-owned subsidiary of
Serologicals Corporation (Nasdaq: SERO). The results of this division
have been accounted for as discontinued operations. Our consolidated
results of continuing operations consist of CMT's contract research
division, Sentigen Biosciences, Inc. and the expenses of the parent
company.

   Consolidated Results of Continuing Operations

   Revenues for the three months ended June 30, 2005 were $1,700,199,
a 44% increase over the revenues of $1,117,973 for the three months
ended June 30, 2004. Our revenues are primarily attributed to our
wholly-owned subsidiary CMT, which accounted for $1,509,026 of our
consolidated revenues for the three months ended June 30, 2005 and a
28% increase when compared to CMT's revenues for the three months
ended June 30, 2004. The remainder of the revenue increase on a
consolidated basis was due to Sentigen Biosciences' contract with the
Technical Support Working Group ("TSWG") an inter-departmental agency
of the federal government with representatives from the Departments of
Defense, State and Homeland Security, to develop advanced
biotechnology for the detection of explosives and other threats, which
initiated in the third quarter of 2004. This contract accounted for
$176,173 of revenue for the three months ended June 30, 2005.
   Revenues for the six months ended June 30, 2005 were $3,461,715, a
38% increase over the $2,508,190 of revenues for the six months ended
June 30, 2004. CMT accounted for $3,106,730 of our consolidated
revenues for the six months ended June 30, 2005 and a 24% increase
when compared to CMT's revenues for the six months ended June 30,
2004. The remainder of the increase on a consolidated basis was
primarily due to Sentigen Biosciences' contract with TSWG. This
contract accounted for $339,985 of revenue for the six months ended
June 30, 2005.
   The loss from continuing operations for the three months ended
June 30, 2005 was ($655,428) or ($0.09) per share. This compares to a
loss from continuing operations of ($752,018) or ($0.10) per share for
the three months ended June 30, 2004. The reduction in loss was due to
an increase in the income from continuing operations of CMT as well as
a reduction in the loss from operations from Sentigen Biosciences.
   The loss from continuing operations for the six months ended June
30, 2005 was ($1,206,659) or ($0.16) per share. This compares to a
loss from continuing operations of ($2,058,781) or ($0.28) per share
for the six months ended June 30, 2004. The reduction in loss was
primarily due to the decline in stock based compensation charges for
the six months ended June 30, 2005. Such charges amounted to $697,439
during the six months ended June 30, 2004, compared to $89,080 for the
six months ended June 30, 2005. The decline is attributable to the
expiration of certain stock option grants to non-employee scientific
consultants. In addition to the decline in stock based compensation,
CMT's increase in income from continuing operations also contributed
to the reduction in loss from continuing operations.

   Results of Continuing Operations by Segment

   The Company operates through two wholly-owned subsidiaries, CMT
and Sentigen Biosciences. The expenses of the parent company, Sentigen
Holding Corp. are reflected in Corporate.
   Cell & Molecular Technologies, Inc. Income from continuing
operations attributable to CMT for the three months ended June 30,
2005 was $233,187 compared to $206,769 for the three months ended June
30, 2004, a 13% increase. Income from continuing operations
attributable to CMT for the six months ended June 30, 2005 was
$530,137 compared to $385,965 for the six months ended June 30, 2004,
a 37% increase. The increase was primarily driven by CMT's increase in
revenues, offset by higher direct costs and selling, general and
administrative expenses.
   Sentigen Biosciences. Sentigen Biosciences has been primarily
engaged in the development and commercialization of novel bioassay
systems that elucidate the underlying biology of protein-protein
interactions. Sentigen Biosciences has initially targeted its
Tango(TM) Assay System to address the functionalization of G
protein-coupled receptors (GPCRs) for pharmaceutical drug discovery
and development. Sentigen Biosciences has filed patent applications on
its Assay System and it expects to file additional patent applications
on this technology and related matters in the future. Sentigen
Biosciences is devoting a significant portion of its research effort
and resources to the development of a novel molecular profiling
system, which if successful, the Company through CMT will attempt to
commercialize.
   While we believe our technology capabilities in the Biosciences
area are substantial, up to this point, Sentigen Biosciences has not
generated any significant revenues and, moreover, has incurred quite
substantial operating losses. Although we have completed several pilot
research collaborations, we have not entered into any drug discovery
or development agreements, nor can any assurance be given that we will
be able to do so on terms that are acceptable to us.
   Management intends to continually review the commercial validity
of the Tango Assay System, its applicability to functionalizing orphan
GPCR's and the prospects of our proposed new novel molecular profiling
system in order to make the appropriate decisions as to the best way
to allocate our limited resources.
   Loss from continuing operations attributable to Sentigen
Biosciences for the three months ended June 30, 2005 was ($455,601) ,
a 9% reduction when compared to the loss from operations of ($500,361)
for the three months ended June 30, 2004. Loss from continuing
operations attributable to Sentigen Biosciences for the six months
ended June 30, 2005 was ($836,474), a 37% improvement when compared to
the loss from operations of ($1,320,793) for the six months ended June
30, 2004. The reduction in loss was primarily due to the absence of
stock-based compensation costs attributable to scientific consultants
as previously discussed, and our contract with TSWG.
   Corporate. Loss from continuing operations attributable to
corporate holding company expenses for the three months ended June 30,
2005 was ($504,489). This compares to a loss attributable to corporate
holding company expenses of ($483,873) for the three months ended June
30, 2004, an increase of 4%. The increase was primarily due to
compensation and commercial insurance expenses. Loss from continuing
operations attributable to corporate holding company expenses for the
six months ended June 30, 2005 was ($1,044,876). This compares to a
loss attributable to corporate holding company expenses of
($1,157,007) for the six months ended June 30, 2004, a reduction of
10%. The reduction is primarily due to a decline in professional fees
for legal services.

   Cash and Working Capital

   At June 30, 2005, the Company had $176,673 in cash and cash
equivalents, $14,072,844 in U.S. Treasury Notes, at market value, and
$13,338,728 in working capital. This compares to $347,560 in cash and
cash equivalents, $9,738,938 in U.S. Treasury Notes, at market value,
and $9,569,381 in working capital at December 31, 2004. It should be
noted that we will need substantial amounts of additional financing to
commercialize the research programs undertaken by us which financing
may not be available or if available may not be on reasonable terms.

-0-
*T

                SENTIGEN HOLDING CORP. AND SUBSIDIARIES
                         FINANCIAL HIGHLIGHTS

Income statement highlights:
----------------------------

                           (Unaudited)             (Unaudited)
                       For the Three Months     For the Six Months
                              Ended                  Ended
                             June 30,               June 30,
                             --------               --------
                        2005        2004        2005        2004
                     ----------  ----------  ----------  ----------
Revenue
  CMT                $1,509,026  $1,177,973  $3,106,730  $2,508,190
  Sentigen
   Biosciences          191,173           -     354,985           -
                     ----------  ----------  ----------  ----------
                      1,700,199   1,177,973   3,461,715   2,508,190

Income after
 direct costs
  CMT                   928,728     781,903   1,925,829   1,585,988
  Sentigen
   Biosciences           79,639           -     143,689           -
                     ----------  ----------  ----------  ----------
                      1,008,367     781,903   2,069,518   1,585,988
Operating
 income/(loss)
  CMT                   233,187     206,769     530,137     385,965
  Sentigen
   Biosciences         (455,601)   (500,361)   (836,474) (1,320,793)
  Corporate            (504,489)   (483,873) (1,044,876) (1,157,007)
                     ----------  ----------  ----------  ----------
Operating (loss)       (726,903)   (777,465) (1,351,213) (2,091,835)
                     ----------  ----------  ----------  ----------
Loss from continuing
 operations            (655,428)   (752,018) (1,206,659) (2,058,781)

(Loss)/income from
 discontinued
 operations, net of
 tax (including gain
 on disposal of
 $4,773,810, net of
 tax for the six
 months ended June
 30, 2005)              (88,200)    242,892   4,835,122     562,332
                     ----------  ----------  ----------  ----------

Net (loss)/income    $ (743,628) $(509,126)  $3,628,463 $(1,496,449)
                     ==========  ==========  ==========  ==========

*T

-0-
*T

Net income (loss) per
 share information:
---------------------
Basic and diluted loss
 per share from
 continuing
 operations          $    (0.09) $    (0.10) $    (0.16) $    (0.28)
                     ==========  ==========  ==========  ==========

Basic and diluted net
 (loss) income per
 share from
 discontinued
 operations          $    (0.01) $     0.03  $     0.65  $     0.08
                     ==========  ==========  ==========  ==========

Basic and diluted
 net (loss) income
 per share           $    (0.10) $    (0.07) $     0.49  $    (0.20)
                     ==========  ==========  ==========  ==========

Weighted average
 shares outstanding:
  Basic and Diluted   7,473,117   7,462,099   7,472,309   7,459,647
                     ==========  ==========  ==========  ==========

*T

-0-
*T

Balance Sheet Highlights:
-------------------------
                                             June 30,   December 31,
                                               2005        2004
                                            ----------- -----------
Cash and cash equivalents                   $   176,673 $   347,560
U.S. treasury notes                          14,072,844   9,738,938
Total current assets                         15,714,129  12,110,677
Total assets                                 16,784,050  13,388,743

Current maturities of long term debt        $   209,809 $   180,698
Current liabilities                           2,375,401   2,541,296
Long-term debt                                  635,046     784,495
Total liabilities                             3,010,447   3,325,791

Stockholder's Equity                        $13,773,603 $10,062,952

*T

   This news release includes forward-looking statements that involve
risks and uncertainties. Although the Company believes such statements
are reasonable, it can make no assurance that such statements will
prove to be correct. Such statements are subject to certain factors
that may cause results to differ materially from the forward-looking
statements. Such factors include the risk factors discussed in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K, a copy of which
may be obtained from the Company without charge. The Company
undertakes no obligation to publicly release results of any of these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unexpected results.

   About Sentigen Holding Corp:

   Sentigen Holding Corp. (NasdaqSC: SGHL) conducts business through
two wholly owned operating subsidiaries, Cell & Molecular
Technologies, Inc. ("CMT"), and Sentigen Biosciences, Inc. Sentigen
Biosciences has been primarily engaged in the development and
commercialization of novel bioassay systems that elucidate the
underlying biology of protein-protein interactions. Sentigen
Biosciences has initially targeted its Tango(TM) Assay System to
address the functionalization of G protein-coupled receptors (GPCRs)
for pharmaceutical drug discovery and development. Sentigen
Biosciences has filed patent applications on its Assay System and it
expects to file additional patent applications on this technology and
related matters in the future. Sentigen Biosciences is devoting a
significant portion of its research effort and resources to the
development of a novel molecular profiling system, which if
successful, the Company through CMT will attempt to commercialize. CMT
provides contract research and development services to companies
engaged in the drug discovery process. For more information on our
companies, please visit their respective websites:
http://www.cmt-inc.net and http://www.sentigen.com.